251 related articles for article (PubMed ID: 28657431)
21. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
[TBL] [Abstract][Full Text] [Related]
23. Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma.
Kuusisto ME; Haapasaari KM; Remes AM; Bloigu R; Karihtala P; Turpeenniemi-Hujanen T; Kuittinen O
Ann Hematol; 2015 Jul; 94(7):1167-74. PubMed ID: 25697593
[TBL] [Abstract][Full Text] [Related]
24. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
26. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica.
Wang H; Wang K; Zhong X; Dai Y; Qiu W; Wu A; Hu X
Neuroimmunomodulation; 2012; 19(5):304-8. PubMed ID: 22777162
[TBL] [Abstract][Full Text] [Related]
27. Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy.
Süße M; Feistner F; Grothe M; Nauck M; Dressel A; Hannich MJ
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32948648
[TBL] [Abstract][Full Text] [Related]
28. Urine neopterin in childhood acute demyelinating diseases: Potential for differential diagnosis.
Kayaoğlu MY; Girgin G; Solmaz I; Baydar T; Anlar B
Mult Scler Relat Disord; 2022 Mar; 59():103662. PubMed ID: 35149394
[TBL] [Abstract][Full Text] [Related]
29. Potential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders.
Fortuna D; Hooper DC; Roberts AL; Harshyne LA; Nagurney M; Curtis MT
PLoS One; 2018; 13(10):e0205501. PubMed ID: 30379898
[TBL] [Abstract][Full Text] [Related]
30. A systematic approach to the diagnosis of suspected central nervous system lymphoma.
Scott BJ; Douglas VC; Tihan T; Rubenstein JL; Josephson SA
JAMA Neurol; 2013 Mar; 70(3):311-9. PubMed ID: 23319132
[TBL] [Abstract][Full Text] [Related]
31. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement.
Hansen PB; Kjeldsen L; Dalhoff K; Olesen B
Acta Neurol Scand; 1992 Mar; 85(3):224-7. PubMed ID: 1575009
[TBL] [Abstract][Full Text] [Related]
33. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
34. CXCL13 and CXCL12 in central nervous system lymphoma patients.
Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal Fluid Flow Cytometry: Utility in Central Nervous System Lymphoma Diagnosis.
Au KLK; Latonas S; Shameli A; Auer I; Hahn C
Can J Neurol Sci; 2020 May; 47(3):382-388. PubMed ID: 32228724
[TBL] [Abstract][Full Text] [Related]
36. Soluble interleukin-2 receptor and soluble CD8 molecules in cerebrospinal fluid and serum of patients with multiple sclerosis.
Carrieri PB; Soscia E; Iacovitti B; Pellicano M; D'Antonio A; Provitera V; Perrella O
Eur Cytokine Netw; 1992; 3(5):495-8. PubMed ID: 1477299
[TBL] [Abstract][Full Text] [Related]
37. Autotaxin and soluble IL-2 receptor concentrations in cerebrospinal fluids are useful for the diagnosis of central nervous system invasion caused by haematological malignancies.
Shimura T; Kurano M; Morita Y; Yoshikawa N; Nishikawa M; Igarashi K; Shimamoto S; Aoki J; Yatomi Y
Ann Clin Biochem; 2019 Mar; 56(2):240-246. PubMed ID: 30514094
[TBL] [Abstract][Full Text] [Related]
38. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.
Rubenstein JL; Wong VS; Kadoch C; Gao HX; Barajas R; Chen L; Josephson SA; Scott B; Douglas V; Maiti M; Kaplan LD; Treseler PA; Cha S; Hwang JH; Cinque P; Cyster JG; Lowell C
Blood; 2013 Jun; 121(23):4740-8. PubMed ID: 23570798
[TBL] [Abstract][Full Text] [Related]
39. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese.
Chan KH; Lee R; Lee JC; Tse AC; Pang SY; Lau GK; Teo KC; Ho PW
J Neuroimmunol; 2013 Sep; 262(1-2):100-5. PubMed ID: 23838529
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy.
Bonin S; Zanotta N; Sartori A; Bratina A; Manganotti P; Trevisan G; Comar M
Immunol Invest; 2018 Feb; 47(2):135-145. PubMed ID: 29182448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
